Lenalidomide

Treatment delays active disease in smoldering myeloma

By

Drug treatment rather than observation may delay disease progression and extend survival in persons with high-risk smoldering multiple myeloma, according to recent study results.

A roundup of FDA news from June 2013

By

FDA-related news items of relevance from the month of June, 2013.

Persistent headache plagues an immunocompromised patient

Persistent headache plagues an immunocompromised patient

Imaging studies and laboratory tests were negative, but lumbar puncture revealed the cause of this patient's unexplained neurologic symptoms.

Combination therapy in multiple myeloma

Combining lenalidomide with low-dose rather than high-dose dexamethasone for the treatment of multiple myeloma improves survival and lowers toxicity, according to the results of a controlled trial

Highly-Effective Drug Regimen Helps Treat Multiple Myeloma Patients

By

Multiple myeloma patients experience high response rates when treated with a drug regimen consisting of 3 drugs, according to data presented at the American Society of Hematology Annual Meeting and Exposition in New Orleans in December.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs